Antidepressant Drug Paxil Birth Defect Trial To Begin Next Week
A Philadelphia court is playing host to what may be the first of three bellwether trials over claims that the antidepressant drug Paxil causes birth defects.
According to plaintiff claims, GlaxoSmithKline, the world’s second-largest drug maker, knew the drug posed a risk but failed to warn consumers. The trial will likely indicate how more than 600 other Paxil birth defect lawsuits will fare, legal experts say.
Patients and their parents claim internal company documents produced for trial show Glaxo failed to warn about the risks of Paxil until forced to do so in 2005 by the U.S. Food and Drug Administration. In a trial set for Sept. 14, Michelle David blames the drug for causing life-threatening heart defects in her 3 year old son, Lyam.
The London-based company faces two more such trials a month from October through January in state court in Philadelphia. The first group will show both sides how the rest of the lawsuits may fare.
The attorneys of Bahe Cook Cantley & Jones PLC represent people injured by unreasonably dangerous drugs and products in Kentucky and Indiana.
